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SPIO Enhance the Cross-Presentation and
Migration of DCs and Anionic SPIO
Influence the Nanoadjuvant Effects Related
to Interleukin-1β
Hui Liu1†, Heng Dong1,2† , Na Zhou1, Shiling Dong1, Lin Chen1, Yanxiang Zhu1, Hong-ming Hu2* and
Yongbin Mou1*
Abstract
Superparamagnetic iron oxide nanoparticles (SPIO) have been synthesized and explored for use as carriers of various
nanoadjuvants via loading into dendritic cells (DCs). In our study, homogeneous and superparamagnetic nanoparticles
are susceptible to internalization by DCs and SPIO-pulsed DCs showed excellent biocompatibility and capacity
for ovalbumin (OVA) cross-presentation. Herein, we found that SPIO-loaded DCs can promote the maturation
and migration of DCs in vitro. SPIO coated with 3-aminopropyltrimethoxysilane (APTS) and meso-2,3-dimercaptosuccinic
acid (DMSA), which present positive and negative charges, respectively, were prepared. We aimed to investigate whether
the surface charge of SPIO can affect the antigen cross-presentation of the DCs. Additionally, the formation of
interleukin-1β (IL-1β) was examined after treatment with oppositely charged SPIO to identify the nanoadjuvants
mechanism. In conclusion, our results suggest that SPIO are biocompatible and can induce the migration of
DCs into secondary lymph nodes. SPIO coated with APTS (SPIO/A+) exhibited excellent adjuvant potentials for
the promotion of antigen cross-presentation and T cell activation and surpassed that of DMSA-coated nanoparticles
(SPIO/D−). This process may be related to the secretion of IL-1β. Our study provides insights into the predictive
modification of nanoadjuvants, which will be valuable in DC vaccine design and could lead to the creation of new
adjuvants for applications in vaccines for humans.
Keywords: Superparamagnetic iron oxide nanoparticles, Dendritic cells, Cross-presentation, Surface charge,
Interleukin-1β, Nanoadjuvant
Background
Adjuvants have been applied extensively for clinical and
experimental use, and they have long been considered as
either immune-stimulatory agents, passive depots, or ve-
hicles that are capable of promoting the required im-
mune responses [1, 2]. In recent decades, many diverse
classes of compounds have been used as adjuvants, in-
cluding nanoparticles, microbial products, emulsions,
cytokines, polymers, and liposomes [3–5]. The evolution
of nanoparticles as immune adjuvants (nanoadjuvants)
represents a remarkable area of antigen delivery based
on magnifying the immune responses. Among all
types of nanoparticles, superparamagnetic iron oxide
nanoparticles (SPIO) have great biocompatibility,
proper surface architecture, and flexible ligand conju-
gation [6]. These properties make them applicable in
many different biomedical areas, such as magnetic
resonance imaging (MRI), targeted drug delivery, and
hyperthermia therapy [7, 8].
Dendritic cells (DCs), the major professional
antigen-presenting cells (APCs), play a critical role in
cell-mediated adaptive immunity in which immuno-
logical memory is generated after a primary response to
a specific antigen, and this memory leads to an enhanced
response to subsequent encounters with that antigen [9,
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10]. In addition, DCs can promote the presentation of
exogenous antigens by major histocompatibility complex
class I (MHC-I), a process called cross-presentation, and
then activate cytotoxic T lymphocytes (CTLs) [11]. Sol-
uble antigens destined for cross-presentation are inter-
nalized by receptor-mediated endocytosis and then
transferred to the cytoplasm for proteasomal degrad-
ation and peptide loading. Conventional DC vaccines
lead to a moderate immune response due to the rela-
tively unsatisfactory transport of soluble antigens. There-
fore, nanoadjuvants have been explored as carriers of
soluble antigens to enhance cross-presentation in DCs
in many research studies [12–14].
Coating materials play critical roles in the stabilization
and subsequent functionalization of aqueous SPIO
suspensions [15]. In previous studies, positively charged
SPIO were shown to facilitate the cross-presentation
ability of DCs to enhance the immune response, and
they surpassed the effect of their oppositely charged
counterparts [16, 17]. The mechanism through which
differently charged SPIO can affect the antigen cross-
presentation of DCs has not been clarified. Interleukin-
1β (IL-1β), a prototypic proinflammatory cytokine that
participates in innate immunity, can be secreted by
immune cells, such as DCs, when sensing pathogen-as-
sociated molecular patterns (PAMPs) and damage-asso-
ciated molecular patterns (DAMPs) [18]. The
production of IL-1β is strictly mediated by inflamma-
somes, especially NLRP3 (NACHT, LRR, and PYD do-
mains-containing protein 3). Activation of NLRP3
induces the production of caspase-1, which then cleaves
inactive pro-IL-1β to the active form IL-1β [19]. Certain
inorganic nanoparticles, such as silica, double-walled
carbon nanotubes, and titanium dioxide, can induce
inflammasome formation [20–22]. Previous studies have
reported a correlation between the surface charge of
magnetite nanoparticles and their cellular efficiency [23].
Herein, we speculate that different surface charges on
SPIO-loaded DCs may also influence the secretion of
IL-1β, and our objective is to investigate the relationship
between these surface charges and the cross-presentation
function of DCs.
Methods and Materials
Preparation of the SPIO
To prepare SPIO, an easy coprecipitation method was
employed as previously reported [24]. In brief, a
mixed solution of FeCl3 and FeSO4 (molar ratio Fe
3
+:Fe2+ = 2:1) was prepared under nitrogen atmosphere
and energetically stirred at 37 °C for 30 min. A
black-colored precipitate of Fe3O4 nanoparticles was
formed and immediately washed five times with dis-
tilled water using magnetic separation. The Fe3O4 was
then dispersed in distilled water to a concentration of
3 mg/mL at a pH of 3. Ultimately, the suspension
was aerated (with air) at 95 °C and the brown SPIO
were separated out.
SPIO coated with DMSA (SPIO/D−) and SPIO
coated with APTS (SPIO/A+) were prepared by coat-
ing SPIO with meso-2,3-dimercaptosuccinic acid
(DMSA) and 3-aminopropyltrimethoxysilane (APTS),
respectively. For SPIO/D−, an aqueous solution of
DMSA at a molar ratio of 1:40 was added to 100 mL
of SPIO solution. After a 4-h reaction with continu-
ous stirring, the SPIO/D− was separated out at a rate
of 500 rpm at 50 °C. For SPIO/A+, APTS was added
to the SPIO solution at a molar ratio of 0.2:1 with
vigorous stirring for 5 h. Then, the precipitate was
dissolved out with a permanent magnet and washed
with deionized water, and the solution was treated
using ultrasonic waves. The resulting solution was
washed repeatedly with water, and the SPIO/A+ were
finally dried into a powder at 37 °C under vacuum.
Mice
C57BL/6 mice and enhanced green fluorescent protein
(EGFP)-transgenic C57BL/6 mice were purchased
from the Model Animal Research Center of Nanjing
University and housed in specific pathogen-free (SPF)
conditions at the Central Laboratory, Nanjing Univer-
sity. All animal experiments were performed in ac-
cordance with protocols approved by the Animal Care
and Use Committee of the Medical School, Nanjing
University, China.
Cell Culture
Murine DCs were generated from mouse bone mar-
row as previously described [25]. In brief, bone mar-
row monocytes of 8-week-old C57BL/6 mice were
separated from their femurs and tibias. Subsequently,
the cells were cultured in RPMI-1640 (Gibco,
Thermo Fisher Scientific, Waltham, MA, USA) along
with 10% fetal bovine serum (FBS), 10 ng/mL mur-
ine granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF; Gibco, USA), and 1 ng/mL murine
interleukin-4 (IL-4, PeproTech, Rocky Hill, NJ,
USA). The culture medium was replaced with fresh
medium every 2 days. Immature DCs were generally
collected on day 6. The EGFP-DCs were derived
from EGFP-transgenic C57BL/6 mice according to
the method mentioned above.
Thawed frozen human peripheral blood mono-
nuclear cells (PBMCs) were rested overnight in
complete medium, i.e., X-VIVOTM 15 (Lonza Group
Ltd., Basel, Switzerland) = 1:1. After density gradient
centrifugation, the PBMCs were suspended in medium
for 4 h. Human DCs from the adherent cells were cul-
tured at 37 °C in medium containing human GM-CSF
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(100 ng/mL; R&D Systems, Minneapolis, MN, USA)
and human IL-4 (10 ng/mL; PeproTech, Rocky Hill,
NJ, USA). Half of the medium was changed on days 2
and 4. Immature human DCs were harvested on day 5.
Cytomegalovirus Epstein-Barr virus and influenza
virus (CEF)-specific T cells were derived from sus-
pended cells, which were cultured in CMX media con-
taining MHC-I restricted CEF peptide (20 ng/mL,
Panatecs, Heilbronn, Germany, PA-CEF-002) for ap-
proximately 48 h. CEF-specific T cells were expanded
by 1000 U/mL human IL-2 (Peprotech, Rocky Hill,
NJ, USA, 200–02) in CMX medium for 12 days. For
IL-2, the medium was replaced with fresh medium
every 3 days.
Characterization
The morphology and size of the SPIO were deter-
mined using a transmission electron microscope
(TEM, Advanced Microscopy Techniques, Danvers,
MA). An X-ray diffraction (XRD) pattern was used to
identify the spectra of the catalyst. The zeta potential
assay was also measured to determine the surface
charges of the nanoparticles coated with different
polymers. The SPIO/A+ and SPIO/D− nanoparticles
were prepared with pH values ranging from 3 to 8.
Zeta potential measurements were made with a zeta-
sizer Nano ZS90 potential analyzer (Malvern, UK).
The magnetic properties of the nanoparticles were an-
alyzed at 37 °C using a vibrating sample magnetom-
eter (Lakeshore 7407).
CPRG Assay
The B3Z T-cell line (a CD8
+ T cell hybridoma) can ex-
press the LacZ gene when its T cell receptor engages an
ovalbumin (OVA) 258–265 epitope in the presence of
the H-2Kb MHC-I molecule. DCs (2 × 104) and OVA
(100 μg/mL, Sigma-Aldrich) were cultured with SPIO,
SPIO/A+, or SPIO/D− at 37 °C. Six hours later, the DCs
were cocultured with B3Z (2 × 10
5) overnight. A chloro-
phenol red-β-galactosidase assay (CPRG, Sigma-Aldrich,
USA) was conducted to determine the β-galactosidase
production of the B3Z cells. In this assay, the optical
density (OD) at 595 nm indicates the antigen
cross-presentation ability of the DCs.
Cells Apoptosis Assay
Fluorescence-activated cell sorting (FCS) was employed
to explore the effects of different concentrations of SPIO
on the viability of DCs. In brief, immature DCs were in-
cubated with SPIO marked with Annexin V and PI
(Biouniquer, CHN), and the expression of Annexin V
and PI in the DCs were examined via FCS.
Fluorescence Intensity Imaging In Vivo
To explore the migration of DCs in vivo, TNF-α (60
ng/mouse) was preinjected into the footpads of both
hind legs (n = 8). After 24 h, SPIO-labeled EGFP-DCs
(2 × 106) in 40 μL of phosphate-buffered saline (PBS)
were injected into the left footpads of C57BL/6 mice,
and the same number of unlabeled EGFP-DCs was
injected into the right side. To examine the level of
EGFP-DCs migrating to the lymph nodes, a Maestro
imaging system (CRi, Woburn, MA, USA) was
employed. The dissected lymph nodes were observed
using 484 nm excitation filters and 507 nm emission
filters. The fluorescent images displaying green fluor-
escence were then analyzed with Living Image soft-
ware (v 2.50; Caliper Corporation, Newton, MA,
USA). Confocal microscopy analyzes were used to de-
termine the immunohistochemistry. Frozen lymph
nodes were cut into 5-μm-thick sections and then
fixed, and the sections were incubated with green
fluorescent protein (GFP) antibody (Invitrogen), with
goat Alexa Fluor 488 nm antibody (Invitrogen) used as
the secondary antibody. A confocal laser scanning
microscope (Fluoview, Fv10i; Olympus) was used to
observe the samples.
Human DC Antigen Cross-Presentation Assay In Vitro
The cultured human DCs (2 × 104) were seeded into a
96-well round-bottomed plate to which SPIO/A+ and
SPIO/D− nanoparticles (100 μg/mL) combined with
cytomegalovirus (CMV) pp65 protein (1 μg/mL,
MACS) were added, and the CMV pp65 protein and
CEF peptide (1 μg/mL, Think peptides) were used
separately as controls. After 6 h, CEF-specific T cells
(2 × 105) were added to the human DCs for 12 h.
Brefeldin A (10 μg/ml, Sigma-Aldrich, USA) was kept
in the medium for another 6 h. After stimulation and
activation, CEF-specific T cells were gathered and
stained with human antibodies against CD3, CD4,
CD8, and IFN-γ (Invitrogen, USA). After staining, the
samples were analyzed by a custom-built LSR II flow
cytometer (BD, Franklin Lakes, NJ, USA). The col-
lected data were analyzed by FlowJo software (Tree
Star, Ashland, OR, USA).
Enzyme-Linked Immunosorbent Assay
A mouse IL-1β enzyme-linked immunosorbent assay
(ELISA) Ready SET-Go kit (eBioscience, USA) and a
human IL-1β ELISA kit (Thermo Fisher Scientific,
Waltham, MA, USA) were employed to determine
the secretion of IL-1β by DCs. An ELISA plate (Co-
star, USA) coated with 100 μL/well of IFN-γ was
used to capture antibodies overnight at 4 °C and
blocked with ELISA buffer. Samples and standards
were then added to the wells and incubated for 2 h
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at 37 °C. Biotinylated IFN-γ was detected. The sam-
ples were measured using a microplate reader with
an OD setting of 450 nm (BioTek, USA).
Statistical Analysis
The data were analyzed using the Statistical Package
for Social Science (SPSS 13.0, Chicago, IL, USA).
The results were presented as the means ± SD, and
differences between the control and test groups were
assessed by a one-way analysis of variance, two-tailed
Student’s t tests, and double-factor analysis of vari-
ance. Differences at *P < 0.05 were considered statis-
tically significant.
Results
Characterization of SPIO
The morphology and size of the synthesized SPIO
were observed via TEM. The TEM image showed
that SPIO had a mean size of 8.7 nm and a spherical
shape (Fig. 1a). The XRD analysis showed six peaks
that distinctly matched the standard γ-Fe2O3 reflec-
tions (Fig. 1b). The vibrating magnetometer results
demonstrated that the obtained SPIO possessed
superparamagnetic behavior, with a saturation
magnetization of 60.4 emu/g better than Fe3O4 (Fig.
1c). The DLS plot showed that the size distribution
of the SPIO is 22 nm in solution (Fig. 1d). To
confirm that the DCs contained SPIO, Prussian blue
staining was performed to verify that the DCs con-
tained iron (Fig. 1e).
SPIO Activated Cross-Presentation of DCs
To further study the effect of SPIO-labeled DCs on T
cell activation in a murine system, the level of B3Z T-cell
activation was determined by examining the production
of β-galactosidase by CPRG assay. A fixed concentration
of 100 μg/mL OVA and five dose ratios of SPIO (1, 5,
10, 25, and 50 μg/mL after 6 h) were adopted in this
study. As the concentration of SPIO increased, the de-
gree of activation of B3Z cells increased gradually and
reached stability at 25 μg/mL (Fig. 2a). To investigate
whether the viability of DCs labeled with the various
concentrations of SPIO was influenced, the DCs and
SPIO-labeled DCs were analyzed via FCS after Annexin
V and PI staining. The results indicated that the total
percentage of Annexin V/PI DCs at SPIO concentrations
of 10, 25, and 50 μg/mL did not significantly differ, while
the percentage of apoptotic cells increased after loading
with 100 μg/mL SPIO (Fig. 2b). The surface costimula-
tory molecules of the DCs labeled with various concen-
trations of SPIO were observed by FCS. The expression
of CD80 and CD86 had a detectable increase at 25 μg/
mL compared with those without SPIO labeling (Fig.
2c). DCs labeled with 25 μg/mL SPIO did not exhibit
changes in cell apoptosis at different time points (Fig.
2d). We used 25 μg/mL in the following experiments.
Fig. 1 Characterization of SPIO. a TEM image of the obtained SPIO. b XRD pattern of the nanoparticle catalyst indicating that the material is γ-Fe2O3. c
Magnetization curves of the obtained SPIO and Fe3O4 nanoparticles. d Hydrodynamic diameter of SPIO. e Morphology of the DCs labeled with 50 μg/
mL SPIO after 12 h of incubation: unlabeled DCs and Prussian blue stain-labeled DCs
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Labelling EGFP-DCs with SPIO Enhanced EGFP Signals in
Secondary Lymph Nodes
EGFP-DCs were successfully derived from EGFP-trans-
genic mice in vitro, and confocal fluorescence micros-
copy images showed that almost all EGFP-DCs exhibited
green fluorescence (Fig. 3a). To investigate whether the
green fluorescence of the EGFP-DCs could be affected
by SPIO, FCS was conducted. The results showed that
the expression of EGFP fluorescence was not weakened
after SPIO labeling (Fig. 3b, c). Then, the 25 μg/mL
SPIO-labeled EGFP-DCs were injected into the
right-side hind footpads of C57BL/6 mice and unlabeled
EGFP-DCs were injected into the opposite side. The
EGFP signals were measured in the popliteal lymph
node (PLN) and inguinal lymph node (ILN), which are
the sentinel lymph nodes and secondary lymph nodes,
respectively. The results showed that the migration of
SPIO-labeled EGFP-DCs and unlabeled EGFP-DCs in
the sentinel lymph nodes reached a peak on day 7. Sig-
nificant differences in the EGFP signal were not ob-
served between the two groups, whereas a significant
reduction was detected in the PLN group on day 14.
The EGFP signals detected in the ILN group were con-
sistent with that of the SPIO-labeled EGFP-DC group on
the 4th day and 7th day, which indicated that the
SPIO-labeled DCs migrated to the secondary lymph
nodes (Fig. 3d–f ).
Differently Charged Modified SPIO Affected Murine DCs
Cross-Presentation
The SPIO were coated with APTS or DMSA. To verify
the surface charge of the SPIO, we measured the zeta
potential characteristic. The zeta potentials of the
SPIO/A+ and SPIO were positive, whereas the zeta po-
tential of the SPIO/D− showed a negative charge in so-
lution when the pH value was 7 (Fig. 4a). The
ultrastructure of the SPIO-labeled DCs coated with dif-
ferently charged polymers was observed via TEM. The
DCs treated with SPIO appeared electron-dense com-
pared with untreated cells, and numerous SPIO were
clustered together in the cytoplasm. The SPIO/A+ were
engulfed by endosomes in the cytoplasm, whereas a
Fig. 2 Influences of DC cross-presentation and biocompatibility after labelling with SPIO. a Cross-presentation of DCs enhanced at different SPIO
concentrations. b Apoptotic DCs and SPIO-labeled DCs examined by FCS at different concentrations (10, 25, 50, and 100 μg/mL). c Phenotypes of
the DCs, including CD11c+CD80+ and CD11c+CD86+ after labelling with SPIO (10, 25, 50 μg/mL). DCs stimulated with LPS (1 μg/mL) were used as
positive controls. d Apoptotic DCs loaded with 25 μg/mL SPIO examined by FCS at different time points (6, 12, 18, and 24 h)
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higher amount of SPIO/D− were found in the cyto-
plasm of the DCs, and nearly all these nanoparticles
were surrounded by several-layered membrane struc-
tures that resembled lysosomes (Fig. 4b). We examined
whether the oppositely charged SPIO could trigger dif-
ferent levels of IL-1β. According to our results, DCs
loaded with SPIO/A+ and SPIO/D− induced a
dose-dependent secretion of IL-1β. Regardless of the
concentration, we found that SPIO/D− induced signifi-
cantly higher levels of IL-1β than SPIO/A+ (Fig. 4c).
Due to the obvious correlation between IL-1β and the
TLR3 pathway, to further study the effect of IL-1β on T
cell activation, DCs were derived from TLR3 knockout
mice and cocultured with SPIO/A+, SPIO/D−, and
OVA. The DCs loaded with SPIO/A+ + OVA could ef-
fectively activate B3Z T cells, which means that the
TLR3 molecule in the DCs was definitely necessary for
cross-presentation (Fig. 4d).
SPIO Modified with Oppositely Charged Coatings
Promoted Antigen Cross-Presentation by Human DCs and
Were Affected by IL-1β
To explore the relationship between IL-1β and cross-pres-
entation, we selected the caspase-1 inhibitor YVAD and
found that it could significantly inhibit the IL-1β secretion
of human DCs after pretreatment with 50 μM lipopolysac-
charide (LPS) for 3 h (Fig. 5a). In addition, we found that
YVAD could inhibit the secretion of IL-1β from human
DCs caused by SPIO/A+ and SPIO/D− (Fig. 5b). We then
investigated whether human DCs could be used as effect-
ive APCs and cross-present CMV pp65 to CEF-specific T
cells. To measure the antigen cross-presentation, intracel-
lular staining (ICS) was introduced to determine the per-
centage of antigen-specific CD3+CD8+IFN-γ+ and
CD3+CD4+IFN-γ+ T cells by FCS. DCs loaded with SPIO/
A+ combined with the CMV pp65 protein induced more
CD3+CD8+IFN-γ+ and CD3+CD4+ IFN-γ+ T cells than
Fig. 3 Migration and location of EGFP-DCs after labelling with SPIO. a Laser scanning confocal microscopy of EGFP-DCs labeled with 25 μg/mL
SPIO nanoparticles after 12 h of incubation. b, c Fluorescence intensity of the SPIO-labeled EGFP-DCs after 12 h. In vitro optical imaging of drainage
lymph nodes after the back transfusion of SPIO-labeled EGFP-DCs at different days. TNF-α was first injected into the mouse foot pad in advance to
promote the migration of EGFP-DCs. d–e In vitro optical imaging and signal intensity analysis of lymph nodes on different days after
injection of EGFP-DCs with or without SPIO. f EGFP positive cells of draining lymph nodes were detected by laser confocal microscopy
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DCs loaded with SPIO/D−. Our data showed that the
caspase-1 inhibitor YVAD significantly increased the T cell
responses induced by the SPIO/D− + CMV pp65
protein, whereas it partly inhibited the T cell
responses induced by the SPIO/A+ + CMV pp65 pro-
tein (Fig. 5c, d). These results indicated that a moder-
ate level of IL-1β activation is needed for efficient
cross-presentation and that a high level of IL-1β acti-
vation suppresses cross-presentation in DCs.
Discussion
Immunotherapy has been a research focus in clinical
and experimental studies since the development of bio-
technology. However, previous clinical trials of trad-
itional DC vaccines designed to elicit immunity have not
induced sufficient immune responses [26]. Nanoparticles
represent a type of adjuvant, and can promote the func-
tion of DCs to activate T cells [27]. The most character-
istic features of our SPIO include their biocompatibility
and their application of labeling DCs as an immune ad-
juvant. The TEM images show that our SPIO have a
mean size of 8.7 nm in the dry state and a spherical
shape (Fig. 1a). Prussian blue staining demonstrated that
the SPIO are susceptible to be phagocytized by DCs
(Fig. 1e), thus indicating the ingestion efficiency.
SPIO have been reported to have broad biomedical
applications, such as in cellular labeling, drug delivery,
MRI, and magnetic hyperthermia [28], which are all
applications that require biocompatibility. Therefore,
whether DCs labeled with SPIO have an influence on
DC apoptosis must be investigated. Our data suggested
that there was no significant difference in DC apoptosis
when DCs were labeled with less than 50 μg/mL SPIO
(Fig. 2b). In the following study, we chose OVA protein
as a model protein and B3Z T cells as effective T cells to
observe whether SPIO can affect the cross-presentation
of DCs. Our results indicate that SPIO-labeled DCs can
markedly facilitate the cross-presentation of OVA and
the activation of B3Z T cells. The surface molecules
CD80 and CD86, which are markers of mature DCs, are
two critical costimulatory factors necessary for T cell ac-
tivation. At 25 μg/mL, the activated B3Z T cells in-
creased with the nanoparticle dose and eventually
stabilized (Fig. 2a). Moreover, the expression of CD80
and CD86 on the surface of DCs reached a maximum
(Fig. 2c). Therefore, we adopted the concentration of
25 μg/mL and found that the apoptosis of DCs is time
independent (Fig. 2d), which proved the excellent
nanoadjuvant functions and biocompatibility of SPIO.
To examine the influence of SPIO on DC migration,
we used EGFP-DCs, which presented green fluorescence
under the confocal fluorescence microscopy, to cocul-
ture with 25 μg/mL SPIO for 12 h. We observed that
the expression of EGFP fluorescence did not weaken
Fig. 4 SPIO coated with differently charges affected DC cross-presentation and IL-1β secretion. a The pH-dependent zeta potential of SPIO coated
with differently charged molecules. b Locations of nanoparticles with different charges in DCs under TEM. c IL-1β induced by SPIO
coated with differently charged molecules. d Cross-presentation of SPIO/A++OVA and SPIO/D− + OVA by DCs through the TLR3 pathway
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after SPIO labeling. Ultimately, the migration of DCs to
the secondary lymphoid organs is the key parameter for
assessing the effectiveness of DC-based vaccines. In our
previous study, over the first 24 h, SPIO-labeled DCs
were not detected in a significant quantity in the sec-
ondary lymph nodes [29]. To further determine whether
this phenomenon changed with time, both labeled and
unlabeled EGFP-DCs were collected and injected into
the foot pads of mice to evaluate the potential of SPIO
in the migration of DCs. Our results showed that green
fluorescence appeared in the ILN on days 4 and 7 (Fig.
3d–f ) thus demonstrating that SPIO can facilitate the
migration of EGFP-DCs to the secondary lymph nodes.
This property can be applied to restrict the metastasis of
tumors and activate a greater amount of CTL cells in
more lymph nodes.
In our study, we have explored the adjuvant properties
of oppositely charged SPIO and the possible mechanism
underlying the changes in the function of DCs. The sur-
face charge of the iron oxide nanoparticles has been
shown to have influence on the cellular uptake efficiency
[30, 31]. In our previous research, we reported that cat-
ionic SPIO could enhance antigen cross-presentation and,
accordingly, T cell activation, while anionic SPIO were as-
sociated with autophagy. [16] Several metal nanoparticles
can induce inflammatory responses [32, 33]. Iron oxide
nanoparticles have been reported to activate NLRP3, rup-
ture the membranes of lysosomes, release cathepsin B,
and induce IL-1β secretion [34]. Thus, we hypothesized
that the oppositely charged SPIO nanoparticles could
serve different functions in stimulating the production of
IL-1β in both murine and human DCs. In Fig. 4a, our zeta
potential analysis showed that APTS-coated SPIO carried
positive charges, whereas DMSA-coated SPIO carried
negative charges. Under the TEM, we found that differ-
ently charged SPIO were clustered in different positions in
the cytoplasm (Fig. 4b). To investigate the difference be-
tween the cross-presentation of SPIO/A+ and SPIO/D−,
we explored IL-1β secretion in murine DCs induced by
differently charged nanoparticles. We assessed the re-
sponses of murine DCs after treatment with SPIO/A+ and
SPIO/D−. Exposure to SPIO/D− induced the overt activa-
tion of IL-1β secretion compared with exposure to SPIO/
A+ (Fig. 4c). This phenomenon partly revealed that the
antigen cross-presentation induced by SPIO/D− is not as
efficient as that induced by SPIO/A+. In addition to the
CPRG analysis of increasing B3Z T cell activation after the
coculture of murine DCs with SPIO/A++OVA demon-
strated that positively charged nanoparticles can perform
better when used as immune adjuvants. Toll-like recep-
tors (TLRs) are of importance for triggering immune re-
sponses, such as TLR3, and they can ultimately result in
Fig. 5 SPIO coated with opposite charges affect the function of human DCs via the IL-1β pathway. a After pre-treatment by LPS for 3 h, human
DCs were incubated with increasing concentrations of YVAD (1, 10, 25, and 50 μM), and then the supernatants were collected for an ELISA of IL-1β. b
YVAD can inhibit the secretion of IL-1β from human DCs via SPIO/D−. SPIO/A+, and SPIO/D− affect the DC cross-presentation influenced by IL-1β. c
CD3+CD8+IFN-γ+ and d CD3+CD4+IFN-γ+ T cells were analyzed by intracellular staining using FCS
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the production of inflammasomes, the activation of
caspase-1 protein, and secretion of cytokine IL-1β [35].
To demonstrate whether TLR3 is related to the antigen
cross-presentation influenced by our nanoadjuvant, TLR3
knockout DCs were employed in our study. TLR3−/− DCs
loaded with SPIO/A++OVA and SPIO + OVA effectively
stimulated the B3Z T cell activation (Fig. 4d), which indi-
cates that the TLR3 molecule in DCs was necessary for
cross-presentation. Collectively, these results elucidated
that differently charged polymers on the surface of nano-
particles should be considered when investigating their
synergistic effects on activated immune responses.
Our data show that the oppositely charged nanoparti-
cles could induce the production of IL-1β, whereas
SPIO/D− could hyperactivate the secretion of IL-1β.
However, compared with SPIO/A+, SPIO/D− induced a
lower level of B3Z T cell activation. Therefore, we specu-
late that aberrant IL-1β production may contribute to
cellular dysfunction in DCs. Most studies on nanomater-
ial adjuvants exploit DCs from mice, whereas few have
used DCs from humans [36, 37]. To further verify our
hypothesis, we used YVAD, which has been proven to be
an effective caspase-1 inhibitor (Fig. 5a, b), to suppress
IL-1β secretion from human DCs. CMV pp65 protein
was selected as the model antigen, and CEF-specific T
cells expanded in vitro were used as responder cells. The
CMV pp65 protein is an immunological dominant pro-
tein that readily activates CD8+ and CD4+ T cells to pro-
duce cytokines, particularly IFN-γ [38]. CEF peptide was
used as a positive control to verify that the addition of
YVAD would not affect the activation of T cells because
it can be presented to the T cells directly. Intriguingly,
with the use of YVAD, the T cell responses in the SPIO/
A+ group were slightly restrained, while the responses in
the SPIO/D− group increased (Fig. 5c, d). The influence
of IL-1β on DC cross-presentation provided conclusive
evidence that a low level of IL-1β induced by SPIO/A+ is
needed for antigen cross-presentation, and a high level
of IL-1β in the cytosol will inhibit the function of DCs.
Conclusions
As shown in the graphical abstract in Fig. 6, SPIO
can promote the maturation, migration, and cross-
presentation of DCs. Moderate IL-1β activity is partly
related to the antigen cross-presentation of DCs. In
addition, negatively charged nanoparticles can activate
excessive IL-1β and subsequently inhibit the functions
of DCs. In summary, our results indicate that SPIO
exhibit many biological properties and have promising
adjuvant potential. These findings will help identify
the optimal choice of nanoadjuvants for the develop-
ment of DC vaccines in the future.
Fig. 6 Graphical abstract of SPIO as a nano-adjuvant for DCs. SPIO enhances the function of DCs by promoting the loading of DCs; thus, SPIO-labeled
DCs can migrate to the ILNs active in an immune organ and may offer a new approach in cancer immunotherapy. Anionic-charged SPIOs activate
protective IL-1β responses by triggering caspase-1 in DCs, thereby impairing antigen presentation to active T cells
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